[go: up one dir, main page]

SI3417883T1 - Tarčni kompleksi, ki oddajajo delec alfa, ki vsebujejo torijev radionuklid in ligand, ki vsebuje hidroksipiridinon - Google Patents

Tarčni kompleksi, ki oddajajo delec alfa, ki vsebujejo torijev radionuklid in ligand, ki vsebuje hidroksipiridinon

Info

Publication number
SI3417883T1
SI3417883T1 SI201131886T SI201131886T SI3417883T1 SI 3417883 T1 SI3417883 T1 SI 3417883T1 SI 201131886 T SI201131886 T SI 201131886T SI 201131886 T SI201131886 T SI 201131886T SI 3417883 T1 SI3417883 T1 SI 3417883T1
Authority
SI
Slovenia
Prior art keywords
hydroxypyridinone
containing ligand
particle emitting
emitting complexes
targeted alpha
Prior art date
Application number
SI201131886T
Other languages
English (en)
Inventor
Thomas Ramdahl
Original Assignee
Bayer As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer As filed Critical Bayer As
Publication of SI3417883T1 publication Critical patent/SI3417883T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI201131886T 2010-02-12 2011-02-14 Tarčni kompleksi, ki oddajajo delec alfa, ki vsebujejo torijev radionuklid in ligand, ki vsebuje hidroksipiridinon SI3417883T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1002508.8A GB201002508D0 (en) 2010-02-12 2010-02-12 Product
EP18163914.7A EP3417883B1 (en) 2010-02-12 2011-02-14 Targeted alpha-particle emitting complexes comprising thorium radionuclide and hydroxypyridinone containing ligand

Publications (1)

Publication Number Publication Date
SI3417883T1 true SI3417883T1 (sl) 2020-07-31

Family

ID=42110714

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201131886T SI3417883T1 (sl) 2010-02-12 2011-02-14 Tarčni kompleksi, ki oddajajo delec alfa, ki vsebujejo torijev radionuklid in ligand, ki vsebuje hidroksipiridinon
SI201131515T SI2533817T1 (sl) 2010-02-12 2011-02-14 Tarčni kompleksi, ki oddajajo delec alfa, ki vsebujejo torijev radionuklid in ligand, ki vsebuje hidroksipiridinon

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201131515T SI2533817T1 (sl) 2010-02-12 2011-02-14 Tarčni kompleksi, ki oddajajo delec alfa, ki vsebujejo torijev radionuklid in ligand, ki vsebuje hidroksipiridinon

Country Status (27)

Country Link
US (2) US9724436B2 (sl)
EP (2) EP2533817B1 (sl)
JP (2) JP5878483B2 (sl)
KR (1) KR101931382B1 (sl)
CN (1) CN103608043B (sl)
AU (1) AU2011214281B2 (sl)
BR (1) BR112012020304B1 (sl)
CA (1) CA2789433C (sl)
CY (1) CY1120362T1 (sl)
DK (2) DK3417883T3 (sl)
EA (1) EA026305B1 (sl)
ES (2) ES2674875T3 (sl)
GB (1) GB201002508D0 (sl)
HR (2) HRP20180996T1 (sl)
HU (2) HUE038013T2 (sl)
IL (2) IL221416A (sl)
LT (2) LT2533817T (sl)
MX (1) MX343405B (sl)
NZ (1) NZ601867A (sl)
PL (2) PL3417883T3 (sl)
PT (2) PT3417883T (sl)
RS (2) RS60314B1 (sl)
SG (1) SG183279A1 (sl)
SI (2) SI3417883T1 (sl)
SM (1) SMT201800325T1 (sl)
TR (1) TR201809149T4 (sl)
WO (1) WO2011098611A2 (sl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2659251C (en) 2006-07-10 2016-06-14 The Regents Of The University Of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
US9273059B2 (en) 2009-08-24 2016-03-01 Lumiphore, Inc. Macrocyclic HOPO chelators
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) * 2012-05-11 2012-06-27 Algeta As Complexes
ES2648096T3 (es) 2013-01-14 2017-12-28 Molecular Insight Pharmaceuticals, Inc. Radiofármacos a base de triazina y agentes de radioformación de imágenes
US11453652B2 (en) 2013-03-15 2022-09-27 Lumiphore, Inc. Di-macrocycles
GB201310028D0 (en) 2013-06-05 2013-07-17 Algeta Asa Pharmaceutical preparation
MA41176A (fr) * 2014-12-17 2017-10-24 Bayer As Complexes radio-pharmaceutiques
US10434186B2 (en) * 2014-12-22 2019-10-08 Lumiphore, Inc. Functionalized linear ligands and complexes thereof
GB201504064D0 (en) 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600161D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope purification method
GB201600153D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
WO2017162555A1 (en) * 2016-03-24 2017-09-28 Bayer Pharma Aktiengesellschaft Radio-pharmaceutical complexes
CR20180581A (es) * 2016-06-10 2019-02-11 Bayer Pharma AG Complejos radio-farmacéuticos
US20200016283A1 (en) 2017-02-24 2020-01-16 Bayer As Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
MX2020006112A (es) 2017-12-13 2020-08-24 Sciencons AS Complejo que comprende un compuesto orientado a psma vinculado a un radionucleido de plomo o torio.
WO2020043617A1 (en) 2018-08-28 2020-03-05 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
US12194111B2 (en) 2018-10-16 2025-01-14 Nant Holdings Ip, Llc Alpha emitter compositions and methods
CA3130747A1 (en) 2019-02-21 2020-08-27 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates
WO2020169538A1 (en) 2019-02-22 2020-08-27 Bayer Aktiengesellschaft Combination of ar antagonists and targeted thorium conjugates
AR119479A1 (es) 2019-07-25 2021-12-22 Bayer As Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer
CA3208778A1 (en) 2021-01-22 2022-07-28 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
WO2025137441A1 (en) 2023-12-22 2025-06-26 Rayzebio, Inc. Radiopharmaceuticals targeting somatostatin receptor 2 and uses thereof
WO2025137443A1 (en) 2023-12-22 2025-06-26 Rayzebio, Inc. Radiopharmaceutical compositions targeting somatostatin receptors and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011475A1 (en) 1988-05-25 1989-11-30 The United States Of America, As Represented By Th Macrocyclic chelates and methods of use thereof
DE69007430T2 (de) 1989-06-19 1994-07-07 Akzo Nobel N.V., Arnheim/Arnhem Radioimmuntherapie unter alphapartikelausstrahlung.
SG52470A1 (en) 1992-04-13 1998-09-28 Dow Chemical Co Process for preparing macrocyclic chelating agents and formation of chelates and conjugates thereof
US5624901A (en) 1994-04-15 1997-04-29 The Regents Of The University Of California 3-hydroxy-2(1H)-pyridinone chelating agents
AU2865995A (en) * 1995-06-14 1997-01-15 Regents Of The University Of California, The 3-hydroxy-2(1h)-pyridinone chelating agents
WO1998016254A1 (en) 1996-10-17 1998-04-23 Immunomedics, Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
WO1998027209A1 (en) 1996-12-18 1998-06-25 Emory University Polycationic oligomers
NO310544B1 (no) 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
NO314537B1 (no) 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
HUP0203743A2 (en) 2000-02-25 2003-02-28 R Keith Frank Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
US7893223B2 (en) * 2001-07-17 2011-02-22 Bracco Imaging S.P.A. Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy
GB0213261D0 (en) 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
US20030228256A1 (en) 2002-06-11 2003-12-11 Inverardi Luca A. Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations
US20030086868A1 (en) 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
ITMI20022411A1 (it) 2002-11-14 2004-05-15 Bracco Imaging Spa Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
NZ543044A (en) * 2003-04-15 2010-04-30 Algeta As Thorium-227 for use in radiotherapy of soft tissue disease
US20060228297A1 (en) 2003-04-15 2006-10-12 Roy Larsen Thorium-227 for use in radiotherapy of soft tissue disease
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
AU2005215234B2 (en) 2004-02-20 2009-02-19 Algeta As Alpha-emitting Hydroxyapatite particles
EP2497501B1 (en) * 2004-06-25 2019-05-01 The European Union, represented by the European Commission Radionuclides for medical use
GB0423565D0 (en) 2004-10-22 2004-11-24 Algeta As Formulation
CA2659251C (en) * 2006-07-10 2016-06-14 The Regents Of The University Of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
EP2051968B1 (en) 2006-08-15 2020-04-29 The Regents of the University of California Luminescent macrocyclic lanthanide complexes
EP2104662A2 (en) * 2007-01-11 2009-09-30 GE Healthcare AS Chelating agents
US20110189088A1 (en) * 2009-12-24 2011-08-04 Lumiphore, Inc. Radiopharmaceutical complexes
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201007354D0 (en) 2010-04-30 2010-06-16 Algeta Asa Method
GB201007353D0 (en) 2010-04-30 2010-06-16 Algeta Asa Method
GB201105298D0 (en) 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes

Also Published As

Publication number Publication date
SI2533817T1 (sl) 2018-08-31
JP5878483B2 (ja) 2016-03-08
LT2533817T (lt) 2018-07-10
KR20120130769A (ko) 2012-12-03
PL2533817T3 (pl) 2018-08-31
DK2533817T3 (en) 2018-07-16
ES2794853T3 (es) 2020-11-19
DK3417883T3 (da) 2020-06-08
US20170319721A1 (en) 2017-11-09
WO2011098611A2 (en) 2011-08-18
KR101931382B1 (ko) 2018-12-20
IL221416A0 (en) 2012-10-31
CN103608043B (zh) 2017-07-28
IL243303A0 (en) 2016-04-21
EA026305B1 (ru) 2017-03-31
GB201002508D0 (en) 2010-03-31
EP3417883A1 (en) 2018-12-26
NZ601867A (en) 2014-11-28
HRP20180996T1 (hr) 2018-08-10
US9724436B2 (en) 2017-08-08
HUE038013T2 (hu) 2018-09-28
CA2789433A1 (en) 2011-08-18
CA2789433C (en) 2019-01-15
PT3417883T (pt) 2020-06-01
BR112012020304A2 (pt) 2016-04-26
MX343405B (es) 2016-11-03
US10682430B2 (en) 2020-06-16
EP3417883B1 (en) 2020-03-25
AU2011214281A1 (en) 2012-08-30
US20130183235A1 (en) 2013-07-18
JP6125599B2 (ja) 2017-05-10
EP2533817A2 (en) 2012-12-19
EP2533817B1 (en) 2018-03-28
MX2012009260A (es) 2013-02-07
JP2016029114A (ja) 2016-03-03
CY1120362T1 (el) 2019-07-10
HUE049465T2 (hu) 2020-09-28
AU2011214281B2 (en) 2014-01-16
ES2674875T3 (es) 2018-07-04
PL3417883T3 (pl) 2020-08-24
JP2013519658A (ja) 2013-05-30
SMT201800325T1 (it) 2018-09-13
LT3417883T (lt) 2020-07-10
WO2011098611A3 (en) 2015-07-02
RS60314B1 (sr) 2020-07-31
IL221416A (en) 2016-03-31
PT2533817T (pt) 2018-06-29
RS57360B1 (sr) 2018-08-31
IL243303A (en) 2017-09-28
EA201290712A1 (ru) 2014-12-30
HRP20200826T1 (hr) 2020-08-07
BR112012020304B1 (pt) 2019-12-10
TR201809149T4 (tr) 2018-07-23
SG183279A1 (en) 2012-09-27
CN103608043A (zh) 2014-02-26

Similar Documents

Publication Publication Date Title
SI3417883T1 (sl) Tarčni kompleksi, ki oddajajo delec alfa, ki vsebujejo torijev radionuklid in ligand, ki vsebuje hidroksipiridinon
ZA201406969B (en) Combination therapy with an anti-hyaluronan agent and a tumor-targreted taxane
EP2820630A4 (en) VIRTUAL GUARDING WITH LOCATION AGENT
SG11201500546RA (en) Vascular access device and guiding portion
IL235905A0 (en) Software agent for core layer security
PT2920167T (pt) Compostos de hidrazinil-indol e conjugados
PT3521208T (pt) Cápsula de porção com código de barras
EP2804646A4 (en) MULTI-DOSES SYRINGE AND ASSOCIATED METHOD
IL251974A0 (en) Antifibrosis compounds and their uses
IL233402B (en) User application for geographic-spatial location information of a released criminal
EP2747839A4 (en) BRACHYTHERAPY DEVICES AND METHOD THEREFOR PROVIDED WITH MICRO-ENCAPED BRACHYTHERAPY MATERIALS
GB201003483D0 (en) Gold complexes
EP2831737A4 (en) SOFTWARE DEVELOPMENT ACTIVITY
GB2505767B (en) A Protection and Carrier System
SI2637704T1 (sl) Ligandi na osnovi radioaktivno označenega fenilimidazola
IL223707A0 (en) N-hydroxyformamide derivative and medicament containing same
PL2852423T3 (pl) System z inhalatora i kapsułki
GB201202622D0 (en) Brachytherapy system & in vivo dose detector therefor
EP2857028A4 (en) AGENT CONTAINING ASCORBIC ACID DERIVATIVE AND USE THEREOF
TWI559972B (en) Microparticle and addition agent
TWM403055U (en) Storage type mouse pad
GB201216381D0 (en) New compounds and medical uses
GB201208970D0 (en) New compounds and medical uses
TWM432365U (en) Incense loop disk structure for hold incense, incense and cyclo incense